Hsa-miR-631 inhibits the migration and invasion of prostate cancer cells by targeting ZAP70 [38] and resensitizes bortezomib-resistant multiple myeloma cells through the inhibition of UbcH10 [39]. Here, UBE2C is linked to plasma cell myeloma.